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Is Worsening Renal Function an Ominous Prognostic Sign
in Patients With Acute Heart Failure?
The Role of Congestion and Its Interaction With Renal Function
Marco Metra, MD; Beth Davison, PhD; Luca Bettari, MD; Hengrui Sun, MD;
Christopher Edwards, BS; Valentina Lazzarini, MD; Barbara Piovanelli, MD; Valentina Carubelli, MD;
Silvia Bugatti, MD; Carlo Lombardi, MD; Gad Cotter, MD; Livio Dei Cas, MD
Background—Worsening renal function (WRF), traditionally defined as an increase in serum creatinine levels 0.3
mg/dL, is a frequent finding in patients with acute heart failure (AHF) and has been associated with poorer outcomes
in some but not all studies. We hypothesized that these discrepancies may be caused by the interaction between WRF
and congestion in AHF patients.
Methods and Results—We measured serum creatinine levels on a daily basis during the hospitalization and assessed the
persistence of signs of congestion at discharge in 599 consecutive patients admitted at our institute for AHF. They had
a postdischarge mortality and mortality or AHF readmission rates of 13% and 43%, respectively, after 1 year. Patients
were subdivided into 4 groups according to the development or not of WRF and the persistence of1 sign of congestion
at discharge. Patients with WRF and no congestion had similar outcomes compared with those with no WRF and no
congestion, whereas the risk of death or of death or AHF readmission was increased in the patients with persistent
congestion alone and in those with both WRF and congestion (hazard ratio, 5.35; 95% confidence interval, 3.0–9.55 at
univariable analysis; hazard ratio, 2.44; 95% confidence interval, 1.24–4.18 at multivariable analysis for mortality;
hazard ratio, 2.14; 95% confidence interval, 1.39–3.3 at univariable analysis; and hazard ratio, 1.39; 95% confidence
interval, 0.88–2.2 at multivariable analysis for mortality and rehospitalizations).
Conclusions—WRF alone, when detected using serial serum creatinine measurements, is not an independent determinant
of outcomes in patients with AHF. It has an additive prognostic value when it occurs in patients with persistent signs
of congestion. (Circ Heart Fail. 2012;5:54-62.)
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Acute heart failure (AHF) is the most important cause ofhospitalization in the United States and Europe.1–3 It
is associated with high in-hospital and postdischarge mortality
and rehospitalization rates. Persistence of signs of congestion
and renal dysfunction have been consistently shown to be among
the most important prognostic variables.2,4–10 Worsening renal
function (WRF), usually defined as an increase in serum creat-
inine levels0.3 mg/dL from values at admission, has also been
shown to be an independent prognostic determinant.8,10–17 Most
of these data were, however, based on retrospective analyses and
they are, therefore, subject to a “detection bias.” For example,
sicker patients who are more congested and have a longer
hospital stay tend to have more creatinine measurements done
and hence have a greater likelihood of showing a creatinine
increase. Second, increases in serum creatinine levels may just
be caused by renal hemodynamic abnormalities and diuretic
therapy.2,4,18 In all of these cases, an increase in serum creatinine
would be simply a marker of more severe HF rather than of real
WRF. In accordance with this hypothesis, studies based on serial
measurements of serum creatinine levels, done independently
from patients’ clinical conditions, have failed to show a prog-
nostic value for the changes of this variable, different from
absolute serum creatinine levels, either on admission or at
discharge.6,19–21
Clinical Perspective on p 62
WRF, as currently defined, based on changes in serum
creatinine levels, may have a different prognostic significance
based on HF severity and, namely, persistence of fluid
overload. We, therefore hypothesized that an interaction
could be shown between changes in serum creatinine levels
(ie, WRF) and signs of congestion with regards of their
association with patient outcomes. With this aim, clinical
signs of congestion and serum creatinine levels were serially
measured, on a daily basis, in consecutive patients hospital-
ized for AHF.
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Methods
Patients
This was a study with the aim of assessing the relationship between
WRF, clinical signs, and prognosis of the patients admitted for AHF.
All the patients hospitalized with a diagnosis of AHF and evaluated
and treated by the authors (Drs Metra, Piovanelli, Bugatti, Lombardi,
Bettari, Carubelli, and Lazzarini) between January 2005 and August
2009 at the Institute of Cardiology of the University and Civil
Hospital of Brescia were included into the study. AHF was diag-
nosed based on the typical symptoms and signs (ie, dyspnea at rest
or minimal effort with signs of pulmonary and/or peripheral conges-
tion) with need of 40 mg intravenous furosemide administration.
We excluded patients with symptoms and/or ECG signs suggestive
of acute coronary syndrome or with arrhythmia, myocarditis, valve
stenosis, cardiac tamponade, aortic dissection, sepsis, or noncardio-
vascular factors as the main cause of symptoms.
Each patient could only contribute once to the database, and, if
multiply admitted, only the first hospitalization occurring during the
period under review was considered in this analysis. Patients
enrolled in randomized, multicenter, intervention trials were also
excluded from the study.
The study was approved by the local ethics committee of the
hospital of Brescia as an observational study. Informed consent was
requested and obtained from each patient recruited before entry into
the study.
Measurements
Each patient underwent a complete clinical and laboratory examina-
tion at the time of admission and during hospitalization. Namely,
signs of congestion (see below) and serum creatinine levels were
assessed and recorded on a daily basis from the time of admission
until discharge. Glomerular filtration rate (in mL/min) was estimated
daily using the simplified Modification of Diet in Renal Disease
equation.22 A Doppler echocardiogram was performed during the
hospitalization to evaluate the systolic left ventricular (LV) function
and the presence of a restrictive LV filling pattern.
Definitions
Congestion was defined as the persistence of 1 or more signs or
symptoms of fluid overload at discharge. The following symptoms
and signs were prospectively considered: third heart sound, pulmo-
nary rales, jugular venous stasis, hepatomegaly, and peripheral
edema. WRF was defined by an absolute increase in serum creatinine
of 0.3 mg/dL from the values measured at the time of admission.
Patients were subdivided in 4 groups, based on the presence or not of
signs of congestion at the time of discharge and on the detection of
WRF during hospitalization. The 4 groups were the following: no
signs of congestion and no WRF (no congestion/no WRF), conges-
tion and no WRF (congestion/no WRF), WRF in the absence of
congestion (no congestion/WRF), and both persistence of congestion
and WRF (congestion/WRF). A history of chronic kidney disease
was defined based on a history of an estimated glomerular filtration
rate 60 mL/min per 1.73 m2.23
With respect of the follow-up data, hospitalization was defined as
any unplanned admission to hospital which required an overnight
stay. Hospitalizations were classified as caused by HF when they
were caused by worsening symptoms of HF with signs of fluid
overload and intravenous furosemide treatment.
Follow-Up
Patients were followed with clinical visits or telephone contacts. The
frequency of follow-up visits was left at the discretion of the
physicians taking care of the patients. However, follow-up informa-
tion was obtained at 3-month intervals, and only 1 patient was lost to
follow-up. Death and HF hospitalizations were the end points of the
study. The composite of death or HF rehospitalization through 1 year
was the primary end point of the study. Patients who underwent heart
transplantation were censored at the time of this procedure. Urgent
heart transplantation was considered as an end-point, equivalent to
death caused by HF.
Statistical Analysis
Values of meanSD are presented for continuous variables and n
(%) for discrete variables unless otherwise specified. Continuous
variables were shown as median and interquartile range (IQR) when
they had a skewed distribution. A probability value 0.05 was
considered statistically significant.
Patient characteristics were compared among groups, using 1-way
ANOVA or the Kruskal-Wallis test for continuous variables and the
Cochran-Mantel-Haenszel 2 for discrete variables.
Two end points were considered to assess the outcome: all-cause
mortality through 1 year (365 days) from discharge and the com-
bined end point of all-cause mortality or hospitalization for HF
through 1 year from discharge. Urgent heart transplant was consid-
ered equivalent to death for these models. Variables related to
outcome at univariable analysis were entered into a multivariable
Cox regression model. Variables that were collinear with another
variable or that had a 10% or more missing values were excluded
from consideration; the presence of an implantable cardioverter-
defibrillator or CRT and the use of medications were also excluded
from consideration in the models because they may be influenced by
the other variables. Indicators for the 4 WRF/congestion groups were
forced into the models. Multivariable models were constructed from
variables having significant associations, with the outcome with
P0.05 using backward selection with a 0.05 significance level for
keeping. Linearity of the association of each predictor and the log
hazard of the outcome was checked by significance of nonlinear
terms for a restricted cubic spline transformation. Variables with a
significantly nonlinear association were modeled with the use of a
restricted cubic spline transformation. The association of each
variable with the outcome is expressed as hazard ratio (HR) and 95%
confidence interval (CI). For continuous variables, the HR is
presented for the 75th versus the 25th percentile of the variable’s
overall distribution. Cumulative survival estimates were calculated
using the Kaplan-Meier method. All the analyses were performed
using SAS release 9.2 (SAS Institute, Inc, Cary, NC).
Results
Patient Characteristics
Five hundred ninety-nine consecutive patients admitted for
AHF were included in this study. Five patients who died on
or before discharge from the initial hospitalization and 1
patient lost to follow-up were excluded from the analyses.
The characteristics of the remaining patients who were
followed up for postdischarge events are shown in Table 1.
Compared with the others, patients with no WRF/no
congestion were younger, less likely to be male, to have
coronary artery disease, chronic obstructive pulmonary dis-
ease, chronic renal disease, and detectable serum troponin
levels during hospitalization. They also had a higher blood
pressure, LV ejection fraction (LVEF), serum hemoglobin,
and serum sodium levels and lower New York Heart Asso-
ciation (NYHA) class, serum creatinine, and blood urea
nitrogen levels. Last, these patients were more likely to
receive an angiotensin-converting enzyme inhibitor or an
angiotensin receptor blocker at discharge, less likely to have
an implantable cardioverter-defibrillator or CRT, received a
lower average daily dose of furosemide, and were less likely
to be treated with intravenous inotropes during the
hospitalization.
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Table 1. Patient Characteristics
Parameters
All
(n594)
WRF and
Cong (n45)
No WRF/Cong
(n31)
WRF/No
Cong (n253)
No WRF/No
Cong (n265)
P
Value
Age, y 69.110.75 69.89.44 69.812.11 70.39.56 67.711.71 0.0378
Sex, male, n (%) 442 (74) 29 (64) 21 (68) 209 (83) 183 (69) 0.0012
Cause of CVD, n (%) CAD 334 (56) 27 (60) 18 (58) 153 (60) 136 (51) 0.1918
History of diabetes, n (%) 206 (35) 17 (38) 14 (45) 95 (38) 80 (30) 0.1744
History of hypertension, n (%) 316 (53) 24 (53) 18 (58) 140 (55) 134 (51) 0.6835
History of atrial fibrillation, n (%) 215 (36) 21 (47) 12 (39) 99 (39) 83 (31) 0.1175
History of heart failure, n (%) 391 (66) 30 (67) 22 (71) 172 (68) 167 (63) 0.6090
COPD, n (%) 121 (20) 17 (38) 8 (26) 55 (22) 41 (15) 0.0043
Chronic kidney disease, n (%) 207 (35) 22 (49) 13 (42) 110 (43) 62 (23) 0.0001
NYHA class at admission
III, n (%) 277 (47) 9 (20) 11 (35) 107 (42) 150 (57) 0.0001
IV, n (%) 317 (53) 36 (80) 20 (65) 146 (58) 115 (43)
NYHA class at discharge
I, n (%) 98 (16) 2 (4) 1 (3) 45 (18) 50 (19) 0.0001
II, n (%) 350 (59) 12 (27) 18 (58) 152 (60) 168 (63)
III, n (%) 136 (23) 23 (51) 10 (32) 56 (22) 47 (18)
IV, n (%) 10 (2) 8 (18) 2 (6) 0 (0) 0 (0)
Systolic blood pressure, mm Hg
Admission 128.729.97 119.630.35 132.632.4 130.432.23 128.327.1 0.1357
Discharge 114.118.32 107.821.99 113.718.33 113.518.4 115.817.38 0.0474
Heart rate, bpm
Admission 8221.28 83.217.73 83.315.65 84.123.2 79.720.36 0.1237
Discharge 68.810.78 72.512.87 70.512.02 68.19.91 68.610.97 0.0712
Weight, kg
Admission 78.216.67 76.615.96 7821.33 78.416.05 78.316.84 0.9271
Discharge 75.315.49 73.814.78 76.120.36 7514.6 75.915.85 0.8072
 from admission to discharge 2.93.61 2.84.53 1.93.26 3.43.72 2.53.3 0.0116
QRS duration, ms 132.238.89 134.637.91 139.937.9 134.640.84 128.637.09 0.2009
Echocardiography
LVEF, % 33.313.79 31.113.97 30.512.84 32.713.31 34.614.25 0.1575
LVEF 50 %, n (%) 111 (19) 6 (13) 3 (10) 46 (18) 56 (21) 0.31
Laboratory characteristics
Serum hemoglobin, mg/dL
Admission 12.81.93 12.31.98 13.21.74 12.71.9 13.11.95 0.0132
Discharge 12.61.79 11.71.74 12.91.83 12.41.75 12.91.76 0.0001
Serum creatinine, mg/dL
Admission 1.60.82 1.70.68 1.70.65 1.71 1.50.64 0.0064
Discharge 1.70.79 2.00.71 1.50.5 1.90.91 1.30.55 0.0001
eGFR, mL/min
Admission 42.820.38 36.814.05 3815.15 41.823.53 45.418.13 0.0142
Discharge 40.518.84 29.110.91 43.116.71 33.114.46 49.319.85 0.0001
eGFR, mL/min, median (IQR)
Admission 47.48 (24.07) 35.7 (18.91) 34.95 (29.59) 38.86 (9.65) 44.87 (24.59) 0.001
Discharge 37.7 (25.44) 25.96 (12.89) 39.53 (25.39) 30.58 (19.39) 46.94 (24.49) 0.0001
BUN, mg/dL
Admission 35.321.25 42.623.41 34.718.21 38.122.34 31.419.37 0.0007
Discharge 38.323.46 51.232.24 33.217.06 45.725.92 30.115.83 0.0001
Serum sodium, mEq/L
Admission 138.73.74 137.94.63 137.54.15 138.73.42 138.93.79 0.0927
Discharge 139.23.68 138.13.9 139.43.24 139.23.71 139.33.65 0.2441
Detectable troponin I admission, n (%) 343 (58) 23 (51) 22 (71) 166 (66) 132 (50) 0.0010
NT-proBNP at discharge, No. of patients,
pg/mL, median (IQR)
265 2033 (1054–4539) 14 2386 (1576–16152) 35 2760 (1056–5476) 72 1951 (1218–4012) 144 1951 (860–4558) 0.0003
(Continued)
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Follow-Up
The median (IQR) duration of the initial hospitalization was
9 (6–15) days. Five patients died on or before the day of
discharge from the initial hospitalization. The remaining 594
patients were discharged alive from hospital, 1 of whom was
lost to follow-up. Data regarding deaths and hospitalizations
were complete for all the other patients. The mean follow-up
of these patients was 797619 days (median [25th, 75th
percentiles], 671 [261, 1275] days) from discharge. Within 1
year after discharge, 78 of these patients died (13.1%), 15
(2.5%) received a transplant, and 219 (36.9%) were rehospi-
talized for AHF.
Determinants of Outcomes
Estimated survival rates in the 4 groups are shown in the
Figure (left). The unadjusted risk of death within 1 year of
discharge in patients with WRF alone was not higher than
in patients with neither WRF nor congestion. However,
patients with both WRF and congestion were at signifi-
cantly higher risk than patients with neither factor. Vari-
ables associated with an increased risk of death within 1
year after discharge at multivariable analysis were chronic
obstructive pulmonary disease, chronic kidney disease,
worse NYHA class, higher heart rate, lower blood pres-
sure, lower body weight, and lower serum sodium (Table
2). After adjustment for these variables, the mortality risks
for patients with either WRF alone or residual congestion
at discharge alone were not significantly greater than that
of patients with neither factor. The increased risk appeared
to be driven primarily by the presence of congestion
(Figure), and the interaction of congestion with WRF was
not statistically significant (P0.3074). Patients with both
Table 1. Continued
Parameters
All
(n594)
WRF and
Cong (n45)
No WRF/Cong
(n31)
WRF/No
Cong (n253)
No WRF/No
Cong (n265)
P
Value
Medications
ACE inhibitors and/or ARBs, n (%)
Admission 449 (76) 30 (67) 25 (81) 186 (74) 208 (78) 0.2599
Discharge 458 (77) 28 (62) 24 (77) 187 (74) 219 (83) 0.0085
Aldosterone antagonists, n (%)
Admission 309 (52) 24 (53) 16 (52) 132 (52) 137 (52) 0.9986
Discharge 402 (68) 32 (71) 22 (71) 175 (69) 173 (66) 0.7514
-Blockers, n (%)
Admission 357 (60) 24 (53) 19 (61) 147 (58) 167 (63) 0.7262
Discharge 477 (80) 31 (69) 27 (87) 209 (83) 210 (79) 0.1305
Furosemide, n (%)
Admission 585 (99) 44 (100) 31 (100) 251 (100) 259 (98) 0.1813
Discharge 564 (95) 45 (100) 31 (100) 241 (95) 247 (93) 0.1239
Furosemide dose, mg/d, meanSD 108.9147.49 230.5202.18 142.7161.43 124.1151.84 71.2113.83 0.0001
Intravenous therapy during
hospitalization
Nitrates, n (%) 179 (30) 12 (27) 13 (42) 89 (35) 65 (25) 0.0238
Inotropes or dopamine, n (%) 148 (25) 18 (40) 7 (23) 80 (32) 43 (16) 0.0001
WRF indicates worsening renal function; Cong, congestion; CVD, cardiovascular disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary
disease; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; IQR, interquartile range; BUN, blood urea
nitrogen; BNP, brain natriuretic peptide; ACE, angiotensin-converting enzyme; ARB, adrenergic receptor binder.
Figure. Outcome for 1-year death or urgent heart transplantation (Tx) (left) and for the combined end point of 1-year death,
urgent heart transplantation, or heart failure (HF) readmission (right) for the patients subdivided on the basis of the development
of worsening renal function (WRF) and on the presence of signs of congestion (Cong) at discharge. The number of patients at risk
is shown at the bottom.
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WRF and residual congestion at discharge had a hazard of
death 3.1 times (95% CI, 1.79 –5.44) the hazard for the
other patients combined.
Estimated HF readmission-free survival rates in the 4
groups are shown in the Figure (right). The pattern of
unadjusted risks was similar to those for mortality, and
similar variables were selected as independent determinants
of death or HF rehospitalization. Namely, age, a history of
chronic renal disease, diabetes, lower systolic blood pressure
at both admission and discharge, higher heart rate at dis-
charge, and lower serum hemoglobin levels at discharge were
found to be significantly associated with increased risk on
multivariable analysis (Table 3). After multivariable adjust-
ment, congestion alone but not WRF alone was associated
with poorer outcome. Having WRF in addition to congestion
placed a patient at a slightly higher risk, but not significantly
(interaction P0.9899). Compared with other patients, pa-
tients with both WRF and residual congestion had 1.37 times
the hazard (95% CI, 0.89 –2.1) for death or HF
rehospitalization.
Discussion
The main finding of our study is that WRF alone, defined as
an increase in serum creatinine levels 0.3 mg/dL from the
values measured on admission, differently from a history of
chronic kidney disease, had no prognostic value in our
patients hospitalized for AHF. However, patients who had
WRF and had persistent signs of congestion at the time of
discharge had an increased risk of death or of death or
rehospitalization, and the association of WRF and persistent
congestion was an independent predictor of outcomes, either
mortality alone or mortality and HF rehospitalizations.
Thus, our analysis suggests that the prognostic value of
changes in serum creatinine levels in patients with AHF is
dependent on the presence of congestion. In the absence of
congestion, increases in serum creatinine levels do not have
prognostic value. In contrast, when serum creatinine levels
increase in patients with concomitant congestion, this is
associated with poorer outcomes.
As proposed above, the notion that creatinine changes
carry significant prognostic value in patients with AHF was
mostly driven by retrospective studies in which creatinine
measurements were not performed routinely in all patients at
multiple time points during admission, such as in the present
study, but rather could have been assessed in the sicker
patients and in those with a longer duration of hospitaliza-
tion.12–15,17, Indeed, this association of serum creatinine in-
creases with outcomes was found to be less prominent in
Table 2. Predictors of Death
Variable
25th, 75th
Percentiles
Death or Transplant
Univariable HR
(95% CI)*
Univariable
P Value
Multivariable HR
(95% CI)*
Multivariable
P Value
Clinical history
CKD 1.83 (1.2, 2.78) 0.005 1.79 (1.15, 2.79) 0.0104
COPD 2.04 (1.29, 3.21) 0.0021 1.87 (1.17, 3) 0.0088
Clinical characteristics
NYHA class, discharge, 4 versus other 7.58 (3.31, 17.39) 0.0001 5.48 (2.02, 14.89) 0.0009
Systolic blood pressure, admission 110, 140 0.53 (0.41, 0.7) 0.0001 0.68 (0.52, 0.88) 0.0031
Systolic blood pressure, discharge 100, 125 0.4 (0.29, 0.56) 0.0001
Heart rate, discharge 60, 75 1.99 (1.53, 2.59) 0.0001 1.48 (1.14, 1.92) 0.0032
Weight, discharge 65.6, 82 0.69 (0.53, 0.89) 0.0051 0.72 (0.55, 0.93) 0.0108
Echocardiographic characteristics
EF, admission 23, 41 0.73 (0.54, 0.98) 0.038
Laboratory characteristics
Plasma hemoglobin, discharge 11.2, 14 0.6 (0.42, 0.84) 0.0035
Serum sodium admission 137, 141 0.6 (0.5, 0.73) 0.0001
Serum sodium, discharge† 137, 142 0.48 (0.27, 0.86) 0.0001 0.69 (0.37, 1.3) 0.0001
Congestion and WRF
1: Yes WRF and yes congestion 5.35 (3, 9.55) 0.0001 2.44 (1.24, 4.81) 0.0097
2: No WRF and yes congestion 1.95 (0.81, 4.7) 0.1364 1.35 (0.52, 3.5) 0.5324
3: Yes WRF and no congestion 1.24 (0.75, 2.03) 0.4037 1.04 (0.62, 1.73) 0.8811
Reference: No WRF and no congestion Ref Ref
CKD indicates chronic kidney disease; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; EF,
ejection fraction; WRF, worsening renal function.
*Hazard ratios (HR) and 95% confidence intervals (CI) are 75th versus 25th percentiles for continuous variables, or presence versus
absence for binary variables.
†Nonlinear relationship with outcome.
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studies in which creatinine assessment was done in a serial
manner in all patients, independent from their clinical
conditions.6,8,19–21
The reasons for the variable prognostic value of serum
creatinine changes can be found in its multiple determinants,
which include local hemodynamic factors influencing the
glomerular filtration pressure, in addition to nephron mass.
Accordingly, an increase in serum creatinine levels has been
often found in patients with relief from congestion. This
occurred in 253 (44%) of our patients and was associated with
a prognosis similar to that of the patients with no WRF and no
congestion. Our patients with WRF and no congestion prob-
ably are similar to those who underwent aggressive decon-
gestion for the treatment of decompensated HF in the ES-
CAPE (Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness) trial. In this
trial, the patients who had hemoconcentration during the
hospitalization, used as an index of enhanced diuretic treat-
ment, received higher doses of loop diuretics, lost more
weight, and had greater reductions in filling pressures
(P0.05 for all). These patients had an increased risk of WRF
(HR, 5.3; P0.001) but also a lower 180-day mortality.24
A similar mechanism probably was the cause of WRF,
defined on the basis of increased serum creatinine levels, in
recent intervention trials. Enhanced diuresis with either rolo-
fylline administration or high-dose furosemide administration
were associated in the PROTECT (Placebo-controlled Ran-
domized study of the selective A(1) adenosine receptor
antagonist rolofylline for patients hospitalized with acute
heart failure and volume Overload to assess Treatment Effect
on Congestion and renal function) and the DOSE (Diuretic
Optimization Strategies Evaluation) trials, respectively, with
a slightly greater rate of episodes of WRF, though with better
dyspnea relief and better short-term outcomes.25–27 Similarly,
serum creatinine bumps were shown with ultrafiltration in a
randomized trial in which this procedure was associated with
greater fluid removal and a lower rehospitalization rate.28 In
these cases, serum creatinine increases probably are second-
ary to arterial underfilling and decreased renal perfusion
pressure caused by enhanced diuresis and/or earlier initiation
Table 3. Predictors of Death or HF Rehospitalization
Variable
25th, 75th
Percentiles
Death, Transplant, or HF Rehospitalization
Univariable HR
(95% CI)*
Univariable
P Value
Multivariable HR
(95% CI)*
Multivariable
P Value
Age† 63, 77 0.64 (0.46, 0.88) 0.0134 0.6 (0.43, 0.82) 0.0061
Clinical history
History of hypertension 0.61 (0.48, 0.78) 0.0001
Previous HF 1.73 (1.31, 2.29) 0.0001
CKD 1.69 (1.32, 2.17) 0.0001 1.43 (1.1, 1.86) 0.0075
Diabetes 1.41 (1.1, 1.81) 0.0075 1.47 (1.12, 1.91) 0.005
Clinical characteristics
Systolic blood pressure, admission 110, 140 0.65 (0.56, 0.76) 0.0001 0.75 (0.65, 0.88) 0.0003
Systolic blood pressure, discharge 100, 125 0.57 (0.47, 0.68) 0.0001 0.68 (0.56, 0.84) 0.0003
Heart rate, admission† 68, 92 1.09 (0.8, 1.5) 0.0079
Heart rate, discharge 60, 75 1.38 (1.17, 1.63) 0.0002 1.33 (1.12, 1.57) 0.0009
QRS duration 99, 161 1.39 (1.15, 1.68) 0.0008
NYHA class, discharge, 4 versus other 2.4 (1.13, 5.08) 0.0226
Echocardiographic characteristics
EF, admission† 23, 41 0.56 (0.39, 0.81) 0.0016
Laboratory characteristics
Plasma hemoglobin, discharge 11.2, 14 0.59 (0.48, 0.72) 0.0001 0.7 (0.57, 0.87) 0.0011
Serum sodium, admission 137, 141 0.76 (0.68, 0.86) 0.0001
Serum sodium, discharge 137, 142 0.77 (0.66, 0.92) 0.0028
Congestion and WRF
1: Yes WRF and yes congestion 2.14 (1.39, 3.3) 0.0005 1.39 (0.88, 2.2) 0.1597
2: No WRF and yes congestion 1.49 (0.86, 2.56) 0.152 1.4 (0.81, 2.42) 0.2247
3: Yes WRF and no congestion 1.24 (0.95, 1.62) 0.1182 0.99 (0.74, 1.31) 0.9225
Reference: No WRF and no congestion Ref Ref
HF indicates heart failure; CKD, chronic kidney disease; NYHA, New York Heart Association; EF, ejection fraction; WRF, worsening
renal function.
*Hazard ratios (HR) and 95% confidence intervals (CI) are 75th versus 25th percentiles for continuous variables or presence versus
absence for binary variables.
†Nonlinear relationship with outcome.
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or uptitration of angiotensin-converting enzyme inhibitors or
adrenergic receptor binders (so-called “vasomotor nephropa-
thy”).2,4,29 These changes in serum creatinine levels are
usually transient and not associated with permanent renal
damage and poor prognosis.
On the other hand, WRF may also be an expression of a
more severe hemodynamic impairment and insufficient
fluid removal in patients with persistent fluid overload.
Namely, low cardiac output and increased central venous
pressure and renal vein pressure may cause a reduction in
the glomerular filtration pressure, WRF, and resistance to
furosemide administration.30 –32 This was the likely mech-
anism of the increased risk of death and of death or HF
rehospitalizations associated with WRF and persistent
congestion in our patients.
If confirmed, these findings suggest that changes in
serum creatinine are not a reliable tool to detect new or
WRF in patients with AHF. This should encourage the
search for novel markers in the urine or blood to detect
acute renal injury. Some new markers (ie, markers of
tubular damage, cystatin-C) have been already tested also
in patients with AHF and have generally provided better
prognostic information than traditional markers of renal
function33–37 However, more research in this area still must
be undertaken.
Our study confirms the ominous prognostic significance of
the persistence of signs of congestion at the time of discharge
in patients admitted for AHF. Persistent congestion was
associated with an increased rate of death or HF rehospital-
ization and, when associated with WRF, with increased
mortality as well. These data are consistent with previous
studies and indicate the limitations of current treatment of
AHF.4,26,38,39
Limitations
The current study represents an analysis of a cohort of
consecutive patients admitted for AHF and evaluated and
treated by the investigators. This may have introduced a
selection bias. Patients dying very early after admission
may have not been included into the study, and this may
explain the relatively low in-hospital mortality of our
patients. On the other hand, the present study is focused on the
relationship between in-hospital changes in serum creatinine
levels and postdischarge outcomes of the patients rather than
in-hospital mortality. Again, because of the characteristics of our
patients, the present study has included mostly patients with
systolic HF. The results should be therefore interpreted with
caution until confirmed in larger less selective prospective
cohorts.
Another limitation of the study is that baseline, except in
a limited sample of patients, and serial biomarker levels
were not measured in this study. Plasma levels of natri-
uretic peptides are related to myocardial wall stress and
have a greater accuracy than clinical signs for the diagno-
sis of congestion. Only clinical signs were used in our
study to diagnose congestion. The diagnostic value of such
assessment is increased when multiple signs are assessed,
as in our study. However, the diagnosis based solely on
clinical signs is less accurate compared when biomarkers
and/or dynamic maneuvers are used.38 In addition, the use
of other biomarkers33–37 and/or of their serial changes
during hospitalization15,36,40 might have yielded a better
prognostic assessment, although this is not generally done
in everyday clinical practice, yet.
Conclusions
In patients with AHF, serum creatinine changes during
admission are associated with adverse outcome only in the
presence of congestion. Persistence of congestion during
the hospitalization is the most important prognostic factor
and WRF has a clinical significance only when occurring
in patients with persistent fluid overload. In patients
without congestion, serum creatinine changes are poten-
tially the result of intensified therapy with diuretics and
angiotensin-converting enzyme inhibitors/adrenergic an-
giotensin receptor blockers and not markers of worsening
HF or kidney function. Better markers of kidney injury
should be explored to detect worsening kidney function or
HF in patients with AHF.
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CLINICAL PERSPECTIVE
An increase in serum creatinine, generally defined as worsening renal function (WRF), is considered an ominous
prognostic sign in patients with heart failure (HF). However, an increase in serum creatinine may be caused by a relative
dehydration secondary to overdiuresis. Thus, the prognostic significance of WRF may depend on the patient’s volume
status. To ascertain this, we measured serum creatinine levels on a daily basis during hospitalization and assessed the
persistence of signs of congestion at discharge in 599 consecutive patients admitted at our institute for acute HF. Patients
with WRF and no congestion had similar outcomes compared with those with no WRF and no congestion, whereas the risk
of death or of death or HF readmission was increased in the patients with persistent congestion alone and in those with both
WRF and congestion. Our data show that WRF has an additive prognostic value only when it occurs in patients with
persistent signs of congestion. Accordingly, the serum creatinine changes occurring in the absence of congestion should
not influence treatment of HF, hospitalization length, and/or be target of HF treatment.
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